Novo Nordisk A/S (NVO) vs Pfizer Inc. (PFE)
- Novo Nordisk A/S NVO 40.33 −4.39%
- Pfizer Inc. PFE 29.96 −2.70%
Novo Nordisk A/S and Pfizer Inc. are both Drug Manufacturers General companies. Pfizer Inc. is the larger, with a market value of $170.3B against $134.8B — 1.3× the size. Novo Nordisk A/S trades at the lower P/E: 9.9× against 42.2×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 1.34%. Novo Nordisk A/S has the higher net margin (35.5% vs 6.34%) and the higher return on invested capital (28.7% vs 6.19%). Both pay a dividend; Pfizer Inc. yields more (7.18% vs 4.45%). Across the 23 metrics below, Novo Nordisk A/S leads on 15 and Pfizer Inc. on 8.
Valuation
Profitability
| Metric | NVO | PFE | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 80.73% | 73.38% | 73.01% |
| Operating margin | 43.36% | 21.44% | 18.34% |
| Net margin | 35.47% | 6.34% | 7.31% |
| Free cash flow margin | 14.79% | 18.52% | 18.52% |
| Return on equity | 60.84% | 4.42% | 5.80% |
| Return on assets | 22.00% | 1.95% | 2.28% |
| Return on invested capital | 28.67% | 6.19% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack